Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
40°
Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Vaccinex Inc
(NQ:
VCNX
)
5.830
-0.101 (-1.70%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Vaccinex Inc
< Previous
1
2
3
4
5
Next >
Earnings Scheduled For May 30, 2023
May 30, 2023
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is projected to report earnings for its first quarter.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
May 24, 2023
It's time for a dive into the biggest pre-market stock movers as we check out all of the latest news for Wednesday morning!
Via
InvestorPlace
Vaccinex Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 15, 2023
From
Vaccinex, Inc.
Via
GlobeNewswire
Why Is Vaccinex (VCNX) Stock Up 67% Today?
February 07, 2023
Vaccinex (VCNX) stock is rocketing higher on Tuesday despite a lack of news from the clinical-stage biotechnology company.
Via
InvestorPlace
Stocks That Hit 52-Week Lows On Wednesday
April 26, 2023
On Wednesday, 345 companies set new 52-week lows.
Via
Benzinga
Vaccinex Completes Enrollment in Phase 1b/2 SIGNAL-AD (Alzheimer’s Disease) Study of Pepinemab
April 25, 2023
From
Vaccinex, Inc.
Via
GlobeNewswire
Vaccinex New ActivMAb® application published in Nature Communications for Directed Evolution of GPCRs in Mammalian Cells
April 12, 2023
From
Vaccinex, Inc.
Via
GlobeNewswire
Vaccinex Announces Private Placement with Commitments of $5.0 Million
April 03, 2023
From
Vaccinex, Inc.
Via
GlobeNewswire
Vaccinex Reports 2022 Financial Results and Provides Corporate Update of Continued Progress in Neurology and Oncology Clinical Programs
April 03, 2023
From
Vaccinex, Inc.
Via
GlobeNewswire
Vaccinex, Inc. to Present at the 2023 AAIC Advancements: Immunity Conference
March 23, 2023
March 24th presentation to highlight learnings related to pepinemab’s mechanism of action in both Huntington’s Disease and Alzheimer’s Disease
From
Vaccinex, Inc.
Via
GlobeNewswire
Vaccinex Announces Initiation of Single-Arm Open Label, Phase Ib/2 Study to Evaluate Pepinemab in Combination with Avelumab as Second Line Combination Immunotherapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
March 21, 2023
From
Vaccinex, Inc.
Via
GlobeNewswire
Vaccinex Reports that KEYNOTE B-84 has Reached Targeted Enrollment for Pre-planned Interim Analysis
March 09, 2023
From
Vaccinex, Inc.
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Tuesday
March 21, 2023
On Tuesday, 74 companies achieved new lows for the year.
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
March 03, 2023
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
March 16, 2023
Thursday's session saw 337 companies set new 52-week lows.
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
February 17, 2023
Via
Benzinga
MarketBeat Week in Review – 2/6 - 2/10
February 11, 2023
Markets are closed the week looking for direction as investors believe a soft landing is not possible and higher interest rates are likely
Via
MarketBeat
Topics
Artificial Intelligence
Economy
Exposures
Artificial Intelligence
Economy
Interest Rates
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
February 08, 2023
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
February 08, 2023
Our coverage starts today with a look at the biggest pre-market stock movers traders will want to keep an eye on Wednesday!
Via
InvestorPlace
Why Sintx Technologies Shares Are Trading Lower By 38%; Here Are 20 Stocks Moving Premarket
February 08, 2023
Gainers PainReform Ltd. (NASDAQ: PRFX) shares rose 89.5% to $0.9475 in pre-market trading. PainReform reported receipt of extension to Aug. 7, 2023 to meet the Nasdaq's minimum bid price requirement.
Via
Benzinga
Should Investors Buy or Sell the Vaccinex Patent News?
February 07, 2023
Shares of Vaccinex, Inc. are higher on February 7 on news that the clinical-stage biotechnology company secured a patent. Is it time to buy or sell the news?
Via
MarketBeat
Topics
Intellectual Property
Exposures
Intellectual Property
Why Is Rubius Therapeutics (RUBY) Stock Down 16% Today?
February 07, 2023
Rubius Therapeutics (RUBY) stock is falling hard on Tuesday after the biotechnology company received a Nasdaq delisting notice.
Via
InvestorPlace
Why Is Bed Bath & Beyond (BBBY) Stock Down 32% Today?
February 07, 2023
Bed Bath & Beyond (BBBY) stock is falling on Tuesday after the retailer revealed plans to raise $1 billion and warned of investing risks.
Via
InvestorPlace
Why Is Oak Street Health (OSH) Stock Up 36% Today?
February 07, 2023
Oak Street Health (OSH) stock is on the rise Tuesday as investors react to a report that CVS (CVS) plans to take over the company.
Via
InvestorPlace
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
February 07, 2023
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
February 07, 2023
It's time to start the day with a breakdown of the biggest pre-market stock movers investors will want to watch on Tuesday!
Via
InvestorPlace
The 3 Best Biotech Stocks Under $1 to Buy for January
January 26, 2023
Even the best small biotech stocks can go bust on a single bad study, but the winners can make their early investors rich.
Via
InvestorPlace
Vaccinex Announces First Patient Dosed with Anti-CCR8 Antibody Licensed to Surface Oncology
January 09, 2023
Surface Oncology initiates clinical trial with antibody discovered using Vaccinex’s ActivMAb® Antibody Discovery Platform
From
Vaccinex, Inc.
Via
GlobeNewswire
Vaccinex Announces $3.8 Million Private Placement
November 28, 2022
From
Vaccinex, Inc.
Via
GlobeNewswire
Vaccinex Reports Third Quarter 2022 Results and Provides Corporate Update
November 14, 2022
Continued Progress in Pepinemab Oncology and Neurology Clinical Programs
From
Vaccinex, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.